Literature DB >> 22990332

Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence.

Ruth Sánchez-Ortiga1, Laura Sánchez-Tejada, Oscar Moreno-Perez, Pedro Riesgo, Maria Niveiro, Antonio M Picó Alfonso.   

Abstract

Some pituitary adenomas (PA) demonstrate aggressive behavior with local invasion and recurrences. Angiogenesis is regarded as an essential step in the formation of solid tumors. The aim of this study is to find out whether angiogenic factors may have information about the aggressiveness of PA that could be useful in determining the frequency of follow-up and whether adjuvant therapy is necessary. In this retrospective descriptive study, we evaluated vascular endothelial growth factors (VEGF) and VEGF receptor (KDR) mRNA expression by RT-PCR analysis on 46 human PA samples. Clinical data, histological subtype and radiologic characteristics were studied to determine the associations between the variables and the pre-operative behavior of the tumor. In addition, we monitored 12 patients without adjuvant post-operative therapies over 46 months after surgery, determining progression of tumor remnants and its association with these markers. VEGF expression correlates with KDR expression (r = 0.40, p = 0.006). VEGF demonstrates different expression between histological subtypes (p = 0.036). The extension at magnetic resonance imaging showed that VEGF expression was related to suprasellar extension (p = 0.007), being expressed more on tumors with extrasellar growth than intrasellar ones (p = 0.008). Our results demonstrate a 27.5 times increased risk of extrasellar growth when VEGF expression exceeds 0.222 normalized copy number (NCN) (p = 0.002). Likewise, tumors with KDR greater than 0.750 NCN had less recurrence-free survival time (p = 0.032). Our results suggest that the expression of VEGF and its receptor could be a marker for poor outcome after partial tumor resection. These data should be considered in future studies evaluating angiogenic factors as therapeutic targets in patients with PA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22990332     DOI: 10.1007/s11102-012-0434-4

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  27 in total

1.  VEGF and CD31 association in pituitary adenomas.

Authors:  Carolina Cristina; María Inés Perez-Millan; Guillermina Luque; Raúl Ariel Dulce; Gustavo Sevlever; Silvia Inés Berner; Damasia Becu-Villalobos
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

2.  Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.

Authors:  M Relf; S LeJeune; P A Scott; S Fox; K Smith; R Leek; A Moghaddam; R Whitehouse; R Bicknell; A L Harris
Journal:  Cancer Res       Date:  1997-03-01       Impact factor: 12.701

Review 3.  Mechanisms of angiogenesis.

Authors:  W Risau
Journal:  Nature       Date:  1997-04-17       Impact factor: 49.962

4.  Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours.

Authors:  Chiara Onofri; Marily Theodoropoulou; Marco Losa; Eberhard Uhl; Manfred Lange; Eduardo Arzt; Günter K Stalla; Ulrich Renner
Journal:  J Endocrinol       Date:  2006-10       Impact factor: 4.286

5.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.

Authors:  N Ferrara; W J Henzel
Journal:  Biochem Biophys Res Commun       Date:  1989-06-15       Impact factor: 3.575

6.  Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas.

Authors:  T Iuchi; N Saeki; K Osato; A Yamaura
Journal:  Acta Neurochir (Wien)       Date:  2000       Impact factor: 2.216

7.  Angiogenesis in pituitary adenomas and the normal pituitary gland.

Authors:  H E Turner; Z Nagy; K C Gatter; M M Esiri; A L Harris; J A Wass
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

8.  The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas.

Authors:  J A C Hunter; R H Skelly; S J B Aylwin; J F Geddes; J Evanson; G M Besser; J P Monson; J M Burrin
Journal:  Eur J Endocrinol       Date:  2003-02       Impact factor: 6.664

9.  Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.

Authors:  Maria Chiara Zatelli; Daniela Piccin; Cristina Vignali; Federico Tagliati; Maria Rosaria Ambrosio; Marta Bondanelli; Vincenzo Cimino; Antonio Bianchi; Herbert A Schmid; Massimo Scanarini; Alfredo Pontecorvi; Laura De Marinis; Giulio Maira; Ettore C degli Uberti
Journal:  Endocr Relat Cancer       Date:  2007-03       Impact factor: 5.678

10.  The association of the expression of vascular endothelial growth factor with the cystic component and haemorrhage in pituitary adenoma.

Authors:  Shinji Fukui; Naoki Otani; Hiroshi Nawashiro; Akiko Yano; Namiko Nomura; Aya M Tokumaru; Takahito Miyazawa; Akira Ohnuki; Nobusuke Tsuzuki; Hiroshi Katoh; Shoichiro Ishihara; Katsuji Shima; Hidetoshi Ooigawa
Journal:  J Clin Neurosci       Date:  2003-05       Impact factor: 1.961

View more
  22 in total

1.  Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas.

Authors:  Mark Gruppetta; Robert Formosa; Sharon Falzon; Sabrina Ariff Scicluna; Edward Falzon; James Degeatano; Josanne Vassallo
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

2.  Identification of gene co-expression modules and hub genes associated with the invasiveness of pituitary adenoma.

Authors:  Yuancheng Zhou; Xiaorui Fu; Zhicheng Zheng; Yu Ren; Zijian Zheng; Bohan Zhang; Min Yuan; Jian Duan; Meihua Li; Tao Hong; Guohui Lu; Dongwei Zhou
Journal:  Endocrine       Date:  2020-04-27       Impact factor: 3.633

Review 3.  Aggressive pituitary adenomas--diagnosis and emerging treatments.

Authors:  Antonio Di Ieva; Fabio Rotondo; Luis V Syro; Michael D Cusimano; Kalman Kovacs
Journal:  Nat Rev Endocrinol       Date:  2014-05-13       Impact factor: 43.330

4.  Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness.

Authors:  Maliheh Ghadir; Mohammad E Khamseh; Mahshid Panahi-Shamsabad; Mohammad Ghorbani; Hamideh Akbari; Ali Zare Mehrjardi; Maryam Honardoost; Bahram Jafar-Mohammadi
Journal:  Endocrine       Date:  2020-07-12       Impact factor: 3.633

5.  Lactotrophs: the new and major source for VEGF secretion and the influence of ECM on rat pituitary function in vitro.

Authors:  Joachim Alfer; Joseph Neulen; Andreas Gaumann
Journal:  Oncol Rep       Date:  2015-03-13       Impact factor: 3.906

6.  Correlations of vascular architecture and angiogenesis with pituitary adenoma histotype.

Authors:  Shingo Takano; Hiroyoshi Akutsu; Takuma Hara; Tetsuya Yamamoto; Akira Matsumura
Journal:  Int J Endocrinol       Date:  2014-11-09       Impact factor: 3.257

Review 7.  Angiogenesis in pituitary adenomas: human studies and new mutant mouse models.

Authors:  Carolina Cristina; Guillermina María Luque; Gianina Demarchi; Felicitas Lopez Vicchi; Lautaro Zubeldia-Brenner; Maria Ines Perez Millan; Sofia Perrone; Ana Maria Ornstein; Isabel M Lacau-Mengido; Silvia Inés Berner; Damasia Becu-Villalobos
Journal:  Int J Endocrinol       Date:  2014-11-18       Impact factor: 3.257

Review 8.  Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor.

Authors:  Andrew L Lin; Mark T A Donoghue; Sharon L Wardlaw; T Jonathan Yang; Lisa Bodei; Viviane Tabar; Eliza B Geer
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

9.  Nonfunctioning giant pituitary adenomas: Invasiveness and recurrence.

Authors:  José Alberto Landeiro; Elissa Oliveira Fonseca; Andrea Lima Cruz Monnerat; Giselle Fernandes Taboada; Gustavo Augusto Porto Sereno Cabral; Felippe Antunes
Journal:  Surg Neurol Int       Date:  2015-11-26

10.  A comparative analysis of ESM-1 and vascular endothelial cell marker (CD34/CD105) expression on pituitary adenoma invasion.

Authors:  Yanming Miao; Miao Zong; Tao Jiang; Xuesen Yuan; Shusen Guan; Yisong Wang; Dabiao Zhou
Journal:  Pituitary       Date:  2016-04       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.